7.00Open7.00Pre Close0 Volume49 Open Interest17.50Strike Price0.00Turnover280.05%IV12.85%PremiumJan 17, 2025Expiry Date4.21Intrinsic Value100Multiplier22DDays to Expiry2.79Extrinsic Value100Contract SizeAmericanOptions Type0.7459Delta0.0212Gamma2.82Leverage Ratio-0.1098Theta0.0052Rho2.10Eff Leverage0.0173Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet